Source - LSE Regulatory
RNS Number : 2209Y
SkinBioTherapeutics PLC
29 December 2023
 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or the "Company")

 

Results of AGM

 

29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held today, all resolutions were duly passed.

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

Resolution

For & Discretionary

Against

Withheld

 

 

Number of votes

%

Number of votes

%

Number of votes

%

01

Ordinary resolution to receive and adopt the directors' and auditors' report and the financial statements for year ended 30 June 2023

43,029,848

96.78%

1,413,649

3.18%

17,051

0.04%

02

Ordinary resolution for Gravita Audit Limited to be re-appointed as the auditors of the Company until the next AGM

42,677,600

95.99%

448,075

1.01%

1,334,873

3.00%

03

Ordinary resolution for the Directors' to be authorised to fix the auditors' remuneration

42,958,431

96.62%

186,707

0.42%

1,315,410

2.96%

04

Ordinary resolution for Stuart Ashman to be re-elected as a Director of the Company

39,303,678

88.40%

2,636,183

5.93%

2,520,687

5.67%

05

Ordinary resolution for Martin Hunt to be re-elected as a Director of the Company

39,991,885

89.95%

2,248,346

5.06%

2,220,317

4.99%

06

Ordinary resolution for Dr Catherine Prescott to be re-elected as a Director of the Company

40,063,946

90.11%

3,072,834

6.91%

1,323,768

2.98%

07

Ordinary resolution for Danielle Bekker to be re-elected as a Director of the Company

42,059,615

94.60%

972,653

2.19%

1,428,280

3.21%

08

Ordinary resolution for Manprit Singh Randhawa to be re-elected as a Director of the Company

39,716,379

89.33%

2,419,340

5.44%

2,324,829

5.23%

09

Ordinary resolution to authorise the directors to allot shares

42,030,813

94.54%

1,096,351

2.47%

1,333,384

3.00%

10

Special resolution to authorise the directors to disapply pre-emption rights

42,285,656

95.11%

822,045

1.85%

1,352,847

3.04%

11

Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment

42,302,981

95.15%

804,720

1.81%

1,352,847

3.04%

 

-Ends-

 

For more information, please contact:

SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO

 

Tel: +44 (0) 191 495 7325

Cavendish Capital Markets Limited

(Nominated Adviser & Broker)

Giles Balleny, Dan Hodkinson
(Corporate Finance)

Charlie Combe (Broking)

Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7220 0500

 

Instinctif Partners (financial press)
Melanie Toyne-Sewell / Jack Kincade 

Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics @instinctif.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGNKCBQKBDDCBB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Skinbiotherapeutics PLC (SBTX)

+0.10p (+0.98%)
delayed 15:57PM